I heard ur question. I listened to the entire session.
nothing to worry about and great prospects, as expected.
Brian also stressed that the company's current market share is still so small compare to its total addressable market. current sales cost recovery period is 12 months but they start to see it will be shorten to 6 months
Symphony won't require additional salespersons. the company is going to ultilise the synergies from its sales team (eg cross-selling).
Ann: Aroa Biosurgery Half Yearly Results H1 FY23, page-8
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
0.015(2.48%) |
Mkt cap ! $213.4M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 62.0¢ | 60.0¢ | $71.70K | 116.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4900 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 50873 | 3 |
View Market Depth
| Last trade - 13.30pm 25/06/2024 (20 minute delay) ? |
| ARX (ASX) Chart |